Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised
TO: